Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

bayer (schweiz) ag - larotrectinibum - capsule - larotrectinibum 25 mg ut larotrectinibi sulfas, kapselhülle: gelatina, e 171, drucktinte: lacca, e 132, e 171, propylenglycolum, dimeticonum 1000, pro capsula. - behandlung von soliden tumoren mit ntrk (neurotrophe tyrosin-rezeptor-kinase)-genfusion - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

bayer (schweiz) ag - larotrectinibum - capsule - larotrectinibum 100 mg ut larotrectinibi sulfas, kapselhülle: gelatina, e 171, drucktinte: lacca, e 132, e 171, propylenglycolum, dimeticonum 1000, pro capsula. - behandlung von soliden tumoren mit ntrk (neurotrophe tyrosin-rezeptor-kinase)-genfusion - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

bayer (schweiz) ag - larotrectinibum - soluzione orale - larotrectinibum 20 mg ut larotrectinibi sulfas, acidum citricum, maltodextrinum, triethylis citras, aromatica (erdbeer) cum alcohol benzylicus, propylenglycolum, hydroxypropylbetadexum 174.6 mg, e 211 2 mg, natrii citras dihydricus, sucralosum, aqua purificata, ad solutionem pro 1 ml corresp. natrium max. 4.17 mg. - behandlung von soliden tumoren mit ntrk (neutrophe tyrosin-rezeptor-kinase)-genfusion - synthetika

Unione Europea - italiano - EMA (European Medicines Agency)

bayer ag - larotrectinib solfato - addominale neoplasie - agenti antineoplastici - vitrakvi come monoterapia è indicato per il trattamento di pazienti adulti e pediatrici con tumori solidi, che mostrano una neurotrophic tirosina chinasi del recettore (ntrk) gene di fusione,che ha una malattia che è localmente avanzato o metastatico in cui la resezione chirurgica è probabile che a causare grave morbilità, andwho sono soddisfacenti opzioni di trattamento.

Unione Europea - italiano - EMA (European Medicines Agency)

roche registration gmbh  - entrectinib - cancer; carcinoma, non-small-cell lung - agenti antineoplastici - rozlytrek as monotherapy is indicated for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (ntrk) gene fusion,who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, andwho have not received a prior ntrk inhibitorwho have no satisfactory treatment options. rozlytrek as monotherapy is indicated for the treatment of adult patients with ros1 positive, advanced non small cell lung cancer (nsclc) not previously treated with ros1 inhibitors.

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

roche pharma (schweiz) ag - entrectinibum - capsule rigide - entrectinibum 100 mg, lactosum 65 mg, cellulosum microcristallinum, acidum tartaricum, hypromellosum, crospovidonum, magnesii stearas, silica colloidalis anhydrica, kapselhülle: hypromellosum, e 171, e 172 (flavum), drucktinte: lacca, propylenglycolum, ammoniae solutio concentrata, e 132, pro capsula. - solide tumoren, nicht-kleinzelliges bronchialkarzinom (nsclc) - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

roche pharma (schweiz) ag - entrectinibum - capsule rigide - entrectinibum 200 mg, lactosum 130 mg, cellulosum microcristallinum, acidum tartaricum, hypromellosum, crospovidonum, magnesii stearas, silica colloidalis anhydrica, kapselhülle: hypromellosum, e 171, e 110 0.5543 mg, drucktinte: lacca, propylenglycolum, ammoniae solutio concentrata, e 132, pro capsula. - solide tumoren, nicht-kleinzelliges bronchialkarzinom (nsclc) - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

janssen-cilag ag - itraconazolum - capsule - itraconazolum 100 mg, hypromellosum, macrogolum 20'000, sacchari sphaerae ut saccharum 175.68 mg et maydis amylum, kapselhülle: gelatina, e 127, e 132, e 171 pro capsula. - antifungini - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

janssen-cilag ag - itraconazolum - capsule - itraconazolum 100 mg, hypromellosum, macrogolum 20'000, sacchari sphaerae ut saccharum 175.68 mg et maydis amylum, kapselhülle: gelatina, e 127, e 132, e 171 pro capsula. - vulvovaginalcandiosis - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

mepha pharma ag - itraconazolum - capsule - itraconazolum 100 mg, sacchari sphaerae corresp. saccharum max. 179.4 mg, hypromellosum, sorbitani stearas, silica colloidalis hydrica, kapselhülle: gelatina, e 171, e 172 (rubrum), pro capsula. - antifungini - synthetika